A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

NCT05274997 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T/NK Cell Lymphoma (R/R PTCL)

Interventions

DRUG: YY-20394

Sponsor

Shanghai YingLi Pharmaceutical Co. Ltd.